Sjögren's disease & overlap diseases
Diagnostic Use of Testing for Novel Murine Autoantibodies for Sjögren Disease in the Rheumatology Outpatient Setting
Authors' conclusion
Testing serum for NA demonstrated a poor ability to distinguish patients with SjD from control patients or those with CS or other ARDs.
Study context
- Population
- Rheumatology outpatients with confirmed Sjögren disease (SjD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), nonspecific chronic sialadenitis, and healthy controls468 screened
- Participants
- 444 outpatients
- Comparison
- Serum testing for three novel autoantibodies (SP-1, parotid secretory protein, CA-6) in SjD vs other autoimmune rheumatic diseases (ARDs), nonspecific chronic sialadenitis and controls
- SjDn = 149
- SLEn = 70
- SScn = 56
- RAn = 73
- Chronic sialadenitis (CS)n = 31reference
- Controlsn = 65reference
- Outcome
- Diagnostic performance of three novel autoantibodies (NA) for SjD: NA prevalence; ROC C-statistics, sensitivity, specificity, positive and negative likelihood ratios for SjD vs CS or controls
Methodological detailsrheumatology outpatient setting
- Rheumatology outpatient setting
Performance
As reported in the abstract
Discrimination of SjD vs CS or controls by serum NA
- Presence of ≥1 novel autoantibodies (NA) in serum, SjD vs other ARDs, CS or controls: no statistical difference
- P = 0.80
- ROC C-statistic, any positive NA, SjD vs CS or controls (poor discriminative ability)
- 0.47
- ROC C-statistic, any individual NA, SjD vs CS or controls (range)
- 0.44-0.53
- Positive likelihood ratio, any positive NA, SjD vs CS
- 1.04
- Positive likelihood ratio, any positive NA, SjD vs controls
- 0.83
Original publication
Diagnostic Use of Testing for Novel Murine Autoantibodies for Sjögren Disease in the Rheumatology Outpatient Setting. Arthritis Care Res (Hoboken). Published 2 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →